Objective:To analyze the mechanism of Kaixin Powder in intervening post-stroke cognitive impairment (PSCI) through network pharmacology and proteomics analysis.Methods:TCMSP, ETCM, TCMID, and BATMAN databases were used to retrieved the active components and gene targets of Kaixin Powder. Differential genes in PSCI patients' blood samples were determined using high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS). A protein-protein interaction network (PPI) was constructed using the STRING database, and a drug-PSCI-gene network was built with Cytoscape software. GO and KEGG enrichment analysis of targets were performed using the DAVID database, and the effective components were docked with targets using AutoDock software for molecular docking verification.Results:A total of 2 292 drug targets within Kaixin Powder were identified, with 248 differential genes found in clinical samples from PSCI patients, including 125 up-regulated and 123 down-regulated genes. KEGG enrichment analysis identified pathways including the TNF signaling pathway, PI3K-Akt signaling pathway, HIF-1 signaling pathway, and MAPK signaling pathway. The molecular docking results indicated that the three active components of Kaixin Powder, β-sitosterol, riboflavin, and musk ketone, had strong binding effects with four target proteins CXCR4, APOE, AGT, and SLC2A1.Conclusion:The active components of Kaixin Powder, such as β-sitosterol, riboflavin, and musk ketone, may treat PSCI by modulating the targets such as CXCR4, APOE, AGT, and SLC2A1, thereby activating or inhibiting pathways such as TNF signaling pathway, PI3K-Akt signaling pathway, HIF-1 signaling pathway, and MAPK signaling pathway.

Objective:To observe the effects of Mongolian medicine warm acupuncture treatment on the behavior and NLRP3, ASC, Caspase-1, GSDMD, and inflammatory factors in hippocampus of the depression model rats; To explore the mechanism.Methods:Totally 40 male SD rats were divided into control group, model group, warm acupuncture group, and fluoxetine group using a random number table method, with 10 rats in each group. Except for the control group, chronic unpredictable stress models were established in all other groups. After 1 hour of daily stress stimulation, the warm acupuncture group received Mongolian medicine warm acupuncture intervention. The fluoxetine group was orally administered with 2.1 mg/kg fluoxetine hydrochloride, while the control group and model group were orally administered with equal volumes of distilled water once a day for 21 days. The body weight of rats was measured, and their behavior was evaluated by sugar water consumption test, open field test, and Morris water maze test. ELISA was used to measure the levels of IL-1 β, IL-18, IL-6, and TNF-α in the serum. Western blot and PCR were used to detect the protein and mRNA levels of NLRP3, ASC, Caspase-1, GSDMD, and IL-1 in the hippocampus.Results:Compared with the model group, the warm acupuncture group and fluoxetine group showed an increase in body weight ( P<0.05), sugar water consumption ( P<0.05), vertical movement frequency and horizontal crossing grid number ( P<0.05), shortened escape latency ( P<0.05), and increased crossing platform frequency ( P<0.05); the levels of serum IL-1β, IL-18, TNF-α, and IL-6 decreased ( P<0.05); the protein and mRNA expressions of NLRP3, Caspase-1, ASC, GSDMD, IL-1β in the hippocampus of rats decreased ( P<0.05). Conclusion:Mongolian medicine warm acupuncture can prevent depressive behaviors in rats by reducing NLRP3-mediated cell death and inflammation.

OBJECTIVE：To explore the new management model of Good Clinical Practice （GCP）trial drug dispensing . METHODS：Base on the relevant experience of Pharmacy Intravenous Admixture Services （PIVAS）in daytime chemotherapy center（“daytime PIVAS ”for short ）of our hospital ，the nodes and other matters needing attention were discussed in the workflow of confirmation and development of drug dispensing tasks for clinical trials. RESULTS ：After the successful approval of the new clinical trial ，the supervisor of the sponsor and the principal investigator should first confirm whether the drugs involved in the project needed to be centrally dispensed in the daytime PIVAS ，and then submitted the relevant data to PIVAS for filing. Daytime PIVAS pharmacists could participate in trial drug dispensing of relevant projects only after starting training and authorization. After the doctor issued the medical order for the subjects in the hospital information system ，the research nurse took the drugs out of the GCP pharmacy and handed them to the daytime PIVAS drug receiving window. After receiving the drugs ，the pharmacist would check the dispensing ，and then the preparation pharmacist trained and authorized by the project team would mix and dispense the drugs. The reviewed pharmacist would check and label the prepared infusion. In addition ，daytime PIVAS would regularly summarize the feedback information on the trial drug dispensing and fund management in all links of dispensing process ，so as to improve the standardization of the process. CONCLUSIONS ：Daytime PIVAS for clinical trial drug can arrange batches more rationally，ensure smooth and orderly infusion ，and meet different drug stability requirements ，which can improve trial drug dispensing management and further promote the development of drug clinical trial projects in China.